Анализ размера, доли и тенденций мирового рынка витреоретинальных заболеваний – обзор отрасли и прогноз до 2033 года.

Размер рынка витреоретинальных заболеваний

• Объем мирового рынка витреоретинальных заболеваний в 2025 году оценивался в 2,17 млрд долларов США  и, как ожидается, достигнет  4,01 млрд долларов США к 2033 году , демонстрируя среднегодовой темп роста в 8,00% в течение прогнозируемого периода.
• Рост рынка в значительной степени обусловлен увеличением распространенности заболеваний сетчатки, таких как диабетическая ретинопатия, возрастная макулярная дегенерация и окклюзия вен сетчатки, а также увеличением численности пожилого населения во всем мире, что приводит к росту спроса на передовые офтальмологические методы лечения.
• Кроме того, растущие достижения в области диагностических методов визуализации, малоинвазивных хирургических процедур и таргетной лекарственной терапии способствуют улучшению результатов лечения пациентов, тем самым превращая витреоретинальное лечение в важнейший компонент современной офтальмологической помощи и значительно стимулируя рост рынка.

Анализ рынка витреоретинальных заболеваний

• Витреоретинальные заболевания, включающие в себя ряд состояний, поражающих сетчатку и стекловидное тело, таких как диабетическая ретинопатия, макулярная дегенерация , отслоение сетчатки и макулярное отверстие, становятся все более важной областью в офтальмологии из-за их значительного влияния на зрение и растущей потребности в своевременной диагностике и лечении как в стационарных, так и в специализированных офтальмологических учреждениях.
• Растущий спрос на витреоретинальные процедуры в первую очередь обусловлен увеличением глобальной распространенности диабета, ростом численности пожилого населения и повышением осведомленности о ранней диагностике заболеваний глаз, а также постоянным совершенствованием технологий визуализации сетчатки, таких как оптическая когерентная томография и ангиография.
• Северная Америка доминировала на рынке витреоретинальных заболеваний, занимая наибольшую долю выручки в 40,01% в 2025 году. Это обусловлено развитой инфраструктурой здравоохранения, широким внедрением инновационных диагностических методов и сильным присутствием ведущих офтальмологических компаний. В США наблюдался значительный рост числа операций на сетчатке, чему способствовали благоприятная политика возмещения расходов и технологические инновации.
• Ожидается, что Азиатско-Тихоокеанский регион станет самым быстрорастущим регионом на рынке витреоретинальных заболеваний в течение прогнозируемого периода благодаря увеличению расходов на здравоохранение, расширению доступа к офтальмологическим услугам и быстрому росту числа больных диабетом.
• В 2025 году сегмент диабетической ретинопатии доминировал на рынке витреоретинальных заболеваний, занимая 43,2% рынка, что обусловлено высокой распространенностью заболевания в мире, тесной связью с ростом числа случаев диабета и увеличением спроса как на диагностические, так и на терапевтические вмешательства.

Обзор отчета и сегментация рынка витреоретинальных заболеваний       

Vitreoretinal Disorders Market Trends

“Advancements in Retinal Imaging and Targeted Therapies”

• A significant and accelerating trend in the global vitreoretinal disorders market is the increasing adoption of advanced diagnostic imaging technologies and targeted treatment approaches for conditions such as Diabetic Retinopathy and Macular Degeneration. This integration of technologies is significantly enhancing early detection and treatment precision
• For instance, optical coherence tomography (OCT) systems and fundus imaging devices are widely used for high-resolution retinal assessment, enabling clinicians to diagnose diseases at earlier stages and monitor disease progression more effectively. Similarly, advanced angiography techniques provide detailed visualization of retinal vasculature, supporting improved clinical decision-making
• Technological advancements in vitreoretinal care enable features such as real-time imaging, minimally invasive surgical guidance, and personalized treatment planning based on disease severity. For instance, some modern imaging platforms incorporate AI to assist in identifying retinal abnormalities and predicting disease progression, thereby enhancing diagnostic accuracy and efficiency. Furthermore, targeted drug delivery systems offer improved therapeutic outcomes with reduced treatment burden for patients
• The seamless integration of diagnostic tools with treatment planning systems facilitates a more coordinated approach to patient care. Through unified ophthalmic platforms, clinicians can manage diagnosis, treatment, and follow-up within a single ecosystem, improving workflow efficiency and patient outcomes
• This trend towards more precise, efficient, and technology-driven retinal care is fundamentally reshaping clinical practices in ophthalmology. Consequently, companies are developing advanced imaging systems and therapeutic solutions with enhanced accuracy, automation, and patient-centric features
• The demand for advanced vitreoretinal diagnostic and treatment solutions is growing rapidly across both developed and emerging healthcare markets, as providers increasingly prioritize early detection and improved management of retinal disorders
• The growing adoption of teleophthalmology and remote retinal screening programs is expanding access to eye care services, particularly in underserved and rural regions, thereby supporting early diagnosis and intervention

Vitreoretinal Disorders Market Dynamics

Driver

“Growing Need Due to Rising Prevalence of Retinal Diseases and Aging Population”

• The increasing prevalence of retinal disorders and the rapidly growing aging population are significant drivers for the heightened demand for vitreoretinal treatments and diagnostic solutions
• For instance, in March 2025, leading ophthalmic companies introduced next-generation retinal imaging devices and therapeutic solutions aimed at improving early diagnosis and treatment outcomes for patients with chronic retinal conditions. Such strategies by key companies are expected to drive the vitreoretinal disorders market growth in the forecast period
• As the global burden of diabetes and age-related eye diseases rises, patients are increasingly seeking early diagnosis and effective treatment options, creating strong demand for advanced vitreoretinal care
• Furthermore, the growing awareness regarding vision health and the importance of regular eye examinations are encouraging early detection and timely intervention, thereby improving clinical outcomes
• The availability of advanced treatment options, including minimally invasive surgeries and pharmacological therapies, along with improved access to ophthalmic care services, are key factors propelling the adoption of vitreoretinal solutions across healthcare settings. The expansion of specialized eye care centers and increasing investment in healthcare infrastructure further contribute to market growth
• Government initiatives and public health programs aimed at reducing vision impairment and blindness are further accelerating the adoption of screening and treatment services
• Increasing collaborations between research institutions and pharmaceutical companies are fostering innovation and accelerating the development of novel therapies for retinal diseases

Restraint/Challenge

“High Treatment Costs and Limited Access to Advanced Care”

• The high cost associated with advanced diagnostic imaging systems, surgical procedures, and long-term treatment regimens poses a significant challenge to the widespread adoption of vitreoretinal care solutions
• For instance, the cost of repeated intravitreal injections and advanced imaging procedures can be substantial, limiting accessibility for patients in low- and middle-income regions
• Addressing these cost-related challenges is crucial for improving patient access to care. Healthcare providers and companies are focusing on developing cost-effective solutions and expanding reimbursement coverage to reduce the financial burden on patients. In addition, limited availability of specialized ophthalmologists and advanced healthcare facilities in rural or underserved areas further restricts access to timely diagnosis and treatment
• While advancements in technology continue to improve treatment outcomes, disparities in healthcare infrastructure and affordability remain key barriers to market growth
• The complexity of treatment regimens, including frequent follow-ups and long-term therapy adherence, can lead to patient non-compliance and suboptimal outcomes
• Regulatory challenges and lengthy approval timelines for advanced therapies, including biologics and gene therapies, can delay market entry and limit the availability of innovative treatment options
• Overcoming these challenges through increased healthcare investment, improved insurance coverage, and the development of affordable diagnostic and treatment options will be vital for sustained market expansion

Vitreoretinal Disorders Market Scope

The market is segmented on the basis of type, diagnosis, treatment, route of administration, end-users, and distribution channel.

• By Type

On the basis of type, the vitreoretinal disorders market is segmented into retinal tear, retinal detachment, Diabetic Retinopathy, Macular Degeneration, macular hole, and others. The diabetic retinopathy segment dominated the market with the largest market revenue share of 43.2% in 2025, driven by its strong association with the rising global prevalence of diabetes and increasing screening initiatives for early detection. The condition requires continuous monitoring and long-term management, leading to sustained demand for diagnostic and therapeutic solutions. In addition, growing awareness regarding diabetic eye complications and improved access to ophthalmic care further contribute to segment dominance. The availability of multiple treatment options, including medications and surgical interventions, also supports its high market share. Increasing healthcare investments and government-led screening programs are further strengthening this segment’s position.

The macular degeneration segment is anticipated to witness the fastest growth rate from 2026 to 2033, fueled by the rapidly aging global population and increasing life expectancy. Age-related macular degeneration is a leading cause of vision loss among elderly individuals, significantly driving demand for advanced therapies and diagnostic tools. Continuous advancements in imaging technologies and targeted treatments are enhancing disease management outcomes. Furthermore, rising awareness and early diagnosis initiatives are accelerating patient inflow for treatment. The development of novel therapies and ongoing clinical research are also contributing to the rapid expansion of this segment.

• By Diagnosis

On the basis of diagnosis, the vitreoretinal disorders market is segmented into digital fluorescein angiography, optical coherence tomography, Heidelberg retinal tomography, indocyanine green angiography, and others. The optical coherence tomography segment dominated the market with the largest market revenue share in 2025, driven by its high-resolution imaging capabilities and non-invasive nature. OCT is widely adopted for early detection, diagnosis, and monitoring of various retinal conditions, making it a standard tool in ophthalmology practices. Its ability to provide real-time cross-sectional images of the retina significantly improves diagnostic accuracy. The growing availability of advanced OCT devices and integration with AI-based analytics further strengthen its dominance. Increasing investments in ophthalmic diagnostic infrastructure also contribute to its widespread use.

The indocyanine green angiography segment is expected to witness the fastest CAGR from 2026 to 2033, driven by its superior capability in visualizing deeper retinal and choroidal blood vessels. This technique is increasingly used in complex retinal disease diagnosis where conventional imaging methods may be insufficient. Growing demand for precise and detailed vascular imaging is accelerating its adoption. Technological advancements and improved imaging systems are enhancing its clinical utility. In addition, rising cases of retinal vascular disorders are further supporting the growth of this segment.

• By Treatment

On the basis of treatment, the vitreoretinal disorders market is segmented into surgery, medication, and others. The medication segment dominated the market with the largest market revenue share in 2025, driven by the widespread use of pharmacological therapies for managing chronic retinal conditions. Medications offer less invasive treatment options and are often preferred for long-term disease management. The increasing availability of targeted therapies and sustained-release drug formulations is enhancing treatment effectiveness. In addition, the rising number of patients requiring ongoing therapy contributes to consistent demand. Improved patient compliance and advancements in drug delivery systems further support segment growth.

The surgery segment is anticipated to witness the fastest growth rate from 2026 to 2033, fueled by advancements in minimally invasive vitreoretinal surgical techniques. Surgical interventions are increasingly required for severe conditions such as retinal detachment and macular hole. Technological innovations in surgical equipment and improved success rates are encouraging adoption. The growing number of specialized ophthalmic centers is also supporting procedural volumes. Furthermore, increasing awareness and accessibility to surgical treatments are driving rapid growth in this segment.

• By Route of Administration

On the basis of route of administration, the vitreoretinal disorders market is segmented into oral, parenteral, ocular, and others. The ocular segment dominated the market with the largest market revenue share in 2025, driven by its direct delivery of drugs to the eye, ensuring higher efficacy and targeted treatment. Ocular administration methods, such as intravitreal injections, are widely used for managing retinal disorders. These approaches minimize systemic side effects while maximizing therapeutic outcomes. Increasing adoption of advanced ocular drug delivery systems is further supporting this segment. The rising prevalence of chronic retinal diseases also contributes to its dominance.

The parenteral segment is expected to witness the fastest CAGR from 2026 to 2033, driven by the growing use of injectable therapies for effective disease management. Parenteral administration ensures rapid drug action and precise dosing, making it suitable for severe retinal conditions. Advancements in biologics and injectable formulations are boosting segment growth. In addition, increasing clinical adoption of injectable treatments is further supporting demand. The expansion of healthcare infrastructure and treatment accessibility also contributes to its rapid growth.

• By End-Users

On the basis of end-users, the vitreoretinal disorders market is segmented into hospitals, specialty clinics, and others. The hospitals segment dominated the market with the largest market revenue share in 2025, driven by the availability of advanced diagnostic and surgical facilities. Hospitals serve as primary centers for complex retinal procedures and comprehensive patient care. The presence of skilled ophthalmologists and access to cutting-edge technologies further strengthen this segment. Increasing patient inflow for diagnosis and treatment also contributes to its dominance. Government support and healthcare investments are enhancing hospital capabilities.

The specialty clinics segment is anticipated to witness the fastest growth rate from 2026 to 2033, fueled by the rising number of dedicated eye care centers. These clinics offer focused and efficient ophthalmic services, attracting a growing patient base. Shorter waiting times and personalized care are key factors driving their popularity. Increasing investments in specialized eye care infrastructure are supporting segment expansion. Furthermore, the growing trend toward outpatient care is accelerating the adoption of specialty clinics.

• By Distribution Channel

On the basis of distribution channel, the vitreoretinal disorders market is segmented into hospital pharmacy, retail pharmacy, and others. The hospital pharmacy segment dominated the market with the largest market revenue share in 2025, driven by the high volume of prescriptions generated within hospital settings. Hospital pharmacies ensure the availability of specialized medications required for retinal treatments. The integration of pharmacy services within hospitals enhances patient convenience and treatment adherence. Increasing hospitalization rates for retinal conditions further support this segment. In addition, strong supply chain networks in hospitals contribute to its dominance.

The retail pharmacy segment is expected to witness the fastest CAGR from 2026 to 2033, driven by increasing accessibility and convenience for patients requiring ongoing medication. Retail pharmacies play a crucial role in dispensing maintenance therapies and follow-up prescriptions. The expansion of pharmacy networks and improved availability of ophthalmic drugs are boosting segment growth. Rising patient preference for easily accessible healthcare services further supports this trend. In addition, the growth of e-pharmacy platforms is enhancing the reach of retail distribution channels.

Vitreoretinal Disorders Market Regional Analysis

• North America dominated the vitreoretinal disorders market with the largest revenue share of 40.01% in 2025, characterized by advanced healthcare infrastructure, high adoption of innovative diagnostic modalities, and a strong presence of leading ophthalmic companies
• Patients and healthcare providers in the region highly value advanced diagnostic imaging technologies, specialized retinal treatments, and well-established ophthalmology infrastructure, which enable effective disease management and improved visual outcomes
• This widespread adoption is further supported by high healthcare expenditure, strong insurance coverage, and a technologically advanced medical ecosystem, along with the presence of leading ophthalmic companies and continuous innovation in retinal therapies, establishing the region as a key hub for vitreoretinal disorder management

U.S. Vitreoretinal Disorders Market Insight

The U.S. vitreoretinal disorders market captured the largest revenue share of 81% in North America in 2025, fueled by the high prevalence of retinal diseases such as Diabetic Retinopathy and Age-related Macular Degeneration, along with strong adoption of advanced ophthalmic diagnostic and treatment solutions. Consumers are increasingly prioritizing early detection and effective management of vision-threatening conditions through advanced retinal imaging and therapeutic interventions. The growing preference for technologically advanced ophthalmic care, combined with robust demand for minimally invasive procedures and innovative biologics, further propels the market. Moreover, the increasing integration of technologies such as optical coherence tomography and anti-VEGF therapies is significantly contributing to market expansion.

Europe Vitreoretinal Disorders Market Insight

The Europe vitreoretinal disorders market is projected to expand at a substantial CAGR throughout the forecast period, primarily driven by the rising aging population, increasing burden of retinal diseases, and growing demand for early diagnosis and preventive eye care. The increase in urbanization, coupled with the demand for advanced ophthalmic services, is fostering the adoption of vitreoretinal treatments and diagnostic technologies. European patients are also drawn to the effectiveness and precision offered by modern retinal imaging systems and minimally invasive procedures. The region is experiencing significant growth across hospitals and specialty eye clinics, with advanced diagnostic tools and therapies being incorporated into both new and existing healthcare infrastructures.

U.K. Vitreoretinal Disorders Market Insight

The U.K. vitreoretinal disorders market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by the escalating prevalence of diabetes-related retinal complications and a strong focus on early diagnosis and treatment. In addition, concerns regarding vision loss and increasing awareness of eye health are encouraging patients and healthcare providers to opt for advanced retinal care solutions. The UK’s robust public healthcare system and expanding ophthalmology services are expected to continue to stimulate market growth.

Germany Vitreoretinal Disorders Market Insight

The Germany vitreoretinal disorders market is expected to expand at a considerable CAGR during the forecast period, fueled by increasing awareness of retinal diseases and demand for advanced, technology-driven ophthalmic solutions. Germany’s well-developed healthcare infrastructure, combined with its emphasis on medical innovation and precision diagnostics, promotes the adoption of vitreoretinal treatments. The integration of retinal imaging technologies with hospital systems is also becoming increasingly prevalent, with a strong preference for high-quality, patient-centric eye care solutions aligning with local healthcare expectations.

Asia-Pacific Vitreoretinal Disorders Market Insight

The Asia-Pacific vitreoretinal disorders market is poised to grow at the fastest CAGR of 24% during the forecast period of 2026 to 2033, driven by increasing prevalence of diabetes, rising geriatric population, and rapid improvements in ophthalmic healthcare access. The region's growing inclination towards advanced eye care, supported by government initiatives promoting healthcare modernization, is driving the adoption of vitreoretinal diagnostic and treatment solutions. Furthermore, as APAC emerges as a major hub for healthcare expansion, the affordability and availability of ophthalmic care are increasing across a wider patient base.

Japan Vitreoretinal Disorders Market Insight

The Japan vitreoretinal disorders market is gaining momentum due to the country’s rapidly aging population, high healthcare standards, and strong demand for advanced retinal disease management. The Japanese market places a significant emphasis on precision medicine and early diagnosis, driving the adoption of advanced imaging technologies and minimally invasive procedures. Moreover, integration of ophthalmic solutions with digital healthcare systems and increasing focus on improving quality of life for elderly patients are further supporting market growth.

India Vitreoretinal Disorders Market Insight

The India vitreoretinal disorders market accounted for the largest market revenue share in Asia Pacific in 2025, attributed to the rapidly growing diabetic population, increasing awareness of eye health, and expanding access to ophthalmic care services. India stands as one of the fastest-growing markets for eye care solutions, and vitreoretinal treatments are becoming increasingly important in both urban and semi-urban regions. The push towards improving healthcare infrastructure, alongside rising affordability of diagnostic and treatment options, are key factors propelling market growth.

Vitreoretinal Disorders Market Share

The Vitreoretinal Disorders industry is primarily led by well-established companies, including:

• F. Hoffmann-La Roche AG (Switzerland)
• Regeneron Pharmaceuticals, Inc. (U.S.)
• Alcon Inc. (Switzerland)
• Bayer AG (Germany)
• Novartis AG (Switzerland)
• Bausch + Lomb Corporation (U.S.)
• Santen Pharmaceutical Co., Ltd. (Japan)
• AbbVie Inc. (U.S.)
• Carl Zeiss Meditec AG (Germany)
• Topcon Corporation (Japan)
• NIDEK CO., LTD. (Japan)
• Ocular Therapeutix, Inc. (U.S.)
• EyePoint Pharmaceuticals, Inc. (U.S.)
• Genentech, Inc. (U.S.)
• Apellis Pharmaceuticals, Inc. (U.S.)
• Kodiak Sciences Inc. (U.S.)
• Clearside Biomedical, Inc. (U.S.)
• Alimera Sciences, Inc. (U.S.)
• STAAR Surgical Company (U.S.)

What are the Recent Developments in Global Vitreoretinal Disorders Market?

• In December 2025, a ranibizumab biosimilar (Nufymco) received FDA approval as an interchangeable therapy for retinal diseases, increasing affordability and access to treatments for diabetic retinopathy and macular degeneration
• В ноябре 2025 года FDA одобрило препарат Eylea HD® (афлиберцепт 8 мг) для лечения макулярного отека, связанного с окклюзией вен сетчатки, что расширило возможности высокодозной терапии анти-VEGF препаратами и улучшило режим дозирования с длительными интервалами для лечения заболеваний сетчатки.
• В мае 2025 года Управление по санитарному надзору за качеством пищевых продуктов и медикаментов США (FDA) одобрило препарат Susvimo® (имплантат ранибизумаба) для лечения диабетической ретинопатии, что стало прорывом в области непрерывной доставки лекарственных средств при заболеваниях сетчатки и значительно снизило необходимость инъекций для пациентов с хроническими витреоретинальными заболеваниями.
• В марте 2025 года продолжалось развитие нормативных требований в области длительной доставки лекарственных препаратов в глаза и терапии сетчатки следующего поколения, при этом многочисленные инновации в разработке препаратов и расширение круга разрешений улучшали долгосрочные результаты лечения витреоретинальных заболеваний.
• В марте 2025 года FDA одобрило препарат Encelto (ревакинаген таротцел), первую генную терапию на основе инкапсулированных клеток для лечения макулярной телеангиэктазии 2 типа, что стало важной вехой в обеспечении длительной доставки лекарственных средств в сетчатку при дегенеративных витреоретинальных заболеваниях.

SKU-53882